Preferred Label : KRAS Mutant Inhibitor BBO-11818;
NCIt synonyms : Pan-KRAS Inhibitor BBO-11818; KRAS Inhibitor BBO-11818;
NCIt definition : An orally bioavailable non-covalent inhibitor of both the active, guanosine triphosphate
(GTP)-bound (ON) form and the inactive, guanosine diphosphate (GDP)-bound (OFF) form
of multiple oncogenic KRAS substitution mutations, including KRAS G12D, G12V and G12X,
with potential antineoplastic activity. Upon oral administration, KRAS mutant inhibitor
BBO-11818 selectively targets and binds to KRAS, thereby inhibiting KRAS-dependent
signaling. This inhibits the growth and survival of KRAS-overexpressing and mutated
tumor cells. KRAS, a member of the RAS family of oncogenes, plays an important role
in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive
signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.;
Molecule name : BBO-11818; BBO 11818;
Origin ID : C216081;
concept_is_in_subset
- has_target
